文献速递脊柱关节炎

轴性脊柱关节炎血脂异常中PCSK9与疾病活动度相关

Proprotein convertase subtilisin/kexin type 9 in the dyslipidaemia of patients with axial spondyloarthritis is related to disease activity.
PubMed 文献 · Rheumatology (Oxford) · 2021-01-01

横断面研究纳入299例轴性脊柱关节炎(axSpA)患者和246例他汀匹配对照,发现axSpA患者PCSK9水平及多项血脂指标显著低于对照;ASDAS-CRP与PCSK9独立正相关,抗TNF-α治疗者PCSK9更低。

要点

  • axSpA患者PCSK9及总胆固醇、HDL-C、LDL-C等血脂指标显著低于对照。
  • ASDAS-CRP与PCSK9独立正相关,提示疾病活动度影响PCSK9水平。
  • 抗TNF-α治疗与PCSK9水平降低相关,泼尼松使用与PCSK9升高相关。

核心结论

  • axSpA患者PCSK9水平下调,疾病活动度与PCSK9正相关,抗TNF-α治疗可降低PCSK9血清水平。

研究设计与样本

  • 横断面研究纳入545人,其中axSpA患者299例,他汀使用匹配的对照246例。
  • 检测患者与对照的PCSK9及标准血脂谱,并在患者中评估颈动脉内膜中层厚度和斑块。
  • 采用多变量分析校正标准心血管危险因素,评估PCSK9对axSpA相关血脂异常和亚临床颈动脉粥样硬化的影响。

主要发现

  • axSpA患者总胆固醇、高密度脂蛋白胆固醇、低密度脂蛋白胆固醇、脂蛋白(a)和载脂蛋白A1显著低于对照。
  • 完全多变量校正后,axSpA患者PCSK9血清水平亦下调[β系数-44 ng/dl(95%CI -60,-27),P=0.000]。
  • 完全校正年龄、性别及其他血脂分子后,ASDAS-CRP与PCSK9独立显著相关[β系数10 ng/dl(95%CI 1,18),P=0.023]。
  • 使用泼尼松的患者PCSK9血清水平更高[55 ng/ml(95%CI 24,8),P=0.001]。
  • 接受抗TNF-α治疗的患者PCSK9水平更低[β系数-26 ng/ml(95%CI -43,-9),P=0.003]。

临床怎么用

  • 在axSpA患者中评估血脂时,需考虑疾病活动度和PCSK9水平的变化。
  • 抗TNF-α治疗可能影响PCSK9水平,解读血脂结果时应结合治疗状态。

局限性

  • 本研究为横断面设计,无法推断因果关系。
  • 颈动脉粥样硬化评估仅在患者中进行,未在对照组开展。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a serine protease that regulates cholesterol metabolism and has been linked to cardiovascular (CV) risk. The purpose of the present study was to examine whether PCSK9 levels are related to abnormalities in the lipid profile and the development of atherosclerosis that occurs in patients with axial SpA (axSpA). METHODS: We performed a cross-sectional study that encompassed 545 individuals; 299 patients with axSpA and 246 statin use-matched controls. PCSK9 and standard lipid profiles were analysed in patients and controls. Carotid intima-media thickness (cIMT) and carotid plaques were assessed in patients. A multivariable analysis, adjusted for standard CV risk factors, was performed to evaluate the influence of PCSK9 on axSpA-related dyslipidaemia and subclinical carotid atherosclerosis. RESULTS: Total cholesterol, high-density lipoprotein and low density lipoprotein cholesterol, lipoprotein (a) and apolipoprotein A1 were significantly lower in axSpA patients than controls. PCSK9 serum levels [β coefficient -44 ng/dl (95% CI -60, -27), P = 0.000] were also downregulated in axSpA patients after fully multivariable adjustment. ASDAS-CRP was found to be independently and significantly related to PCSK9 [β coefficient 10 ng/dl (95% CI 1, 18), P = 0.023] after analysing fully adjusted models that took age, sex and the rest of the lipid profile molecules into account. Whereas patients taking prednisone showed higher serum levels of PCSK9 [55 ng/ml (95% CI 24, 8), P = 0.001], those under anti-TNF-α therapies exhibited lower levels [β coefficient -26 ng/ml (95% CI -43, -9], P = 0.003]. CONCLUSION: PCSK9 is downregulated in patients with axSpA. Disease activity is positive and significantly related to PSCK9. Anti-TNF-therapy yields a reduction in PCSK9 serum levels.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. de Armas-Rillo L, Quevedo-Abeledo JC, de Vera-González A, et al. Proprotein convertase subtilisin/kexin type 9 in the dyslipidaemia of patients with axial spondyloarthritis is related to disease activity. Rheumatology (Oxford). 2021. PMID: 33295631. doi:10.1093/rheumatology/keaa590

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。